[go: up one dir, main page]

FI891020L - Menetelmä proteaasi-inhibiittoriaktiivisuutta omaavien egliinimutanttien valmistamiseksi - Google Patents

Menetelmä proteaasi-inhibiittoriaktiivisuutta omaavien egliinimutanttien valmistamiseksi Download PDF

Info

Publication number
FI891020L
FI891020L FI891020A FI891020A FI891020L FI 891020 L FI891020 L FI 891020L FI 891020 A FI891020 A FI 891020A FI 891020 A FI891020 A FI 891020A FI 891020 L FI891020 L FI 891020L
Authority
FI
Finland
Prior art keywords
preparing
protease inhibitor
inhibitor activity
eglin mutants
eglin
Prior art date
Application number
FI891020A
Other languages
English (en)
Swedish (sv)
Other versions
FI96116B (fi
FI891020A0 (fi
FI96116C (fi
Inventor
Markus Gerhard Gruetter
Dirk Heinz
Manfred Liersch
Original Assignee
Ciba Geigy Ag
Ucp Gen Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy Ag, Ucp Gen Pharma Ag filed Critical Ciba Geigy Ag
Publication of FI891020A0 publication Critical patent/FI891020A0/fi
Publication of FI891020L publication Critical patent/FI891020L/fi
Publication of FI96116B publication Critical patent/FI96116B/fi
Application granted granted Critical
Publication of FI96116C publication Critical patent/FI96116C/fi

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55Protease inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81Protease inhibitors
    • C07K14/815Protease inhibitors from leeches, e.g. hirudin, eglin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8261Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield
    • C12N15/8271Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance
    • C12N15/8279Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance for biotic stress resistance, pathogen resistance, disease resistance
    • C12N15/8286Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance for biotic stress resistance, pathogen resistance, disease resistance for insect resistance
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A40/00Adaptation technologies in agriculture, forestry, livestock or agroalimentary production
    • Y02A40/10Adaptation technologies in agriculture, forestry, livestock or agroalimentary production in agriculture
    • Y02A40/146Genetically Modified [GMO] plants, e.g. transgenic plants
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/855Proteins from animals other than mammals or birds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Pest Control & Pesticides (AREA)
  • Insects & Arthropods (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
FI891020A 1988-03-07 1989-03-03 Menetelmä proteaasi-inhibiittoriaktiivisuutta omaavien egliinimutanttien valmistamiseksi FI96116C (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH84088 1988-03-07
CH84088 1988-03-07

Publications (4)

Publication Number Publication Date
FI891020A0 FI891020A0 (fi) 1989-03-03
FI891020L true FI891020L (fi) 1989-09-08
FI96116B FI96116B (fi) 1996-01-31
FI96116C FI96116C (fi) 1996-05-10

Family

ID=4196431

Family Applications (1)

Application Number Title Priority Date Filing Date
FI891020A FI96116C (fi) 1988-03-07 1989-03-03 Menetelmä proteaasi-inhibiittoriaktiivisuutta omaavien egliinimutanttien valmistamiseksi

Country Status (20)

Country Link
US (1) US5079229A (fi)
EP (1) EP0332576B1 (fi)
JP (1) JP2716191B2 (fi)
KR (1) KR0134377B1 (fi)
AT (1) ATE103930T1 (fi)
AU (1) AU623881B2 (fi)
CA (1) CA1339105C (fi)
DD (1) DD283645A5 (fi)
DE (1) DE58907373D1 (fi)
DK (1) DK107389A (fi)
ES (1) ES2063161T3 (fi)
FI (1) FI96116C (fi)
HU (1) HU209401B (fi)
IE (1) IE62993B1 (fi)
IL (1) IL89496A0 (fi)
NO (1) NO178870C (fi)
NZ (1) NZ228208A (fi)
PT (1) PT89916B (fi)
TW (1) TW211522B (fi)
ZA (1) ZA891679B (fi)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6342373B1 (en) * 1983-11-21 2002-01-29 Ucp Gen-Pharma Ag Process for preparing recombinant eglin, protease inhibitor
US5674833A (en) * 1990-09-18 1997-10-07 Novo Nordisk A/S Detergent compositions containing protease and novel inhibitors for use therein
US5604201A (en) * 1993-01-08 1997-02-18 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non-Profit Organization Methods and reagents for inhibiting furin endoprotease
TW492975B (en) * 1993-07-26 2002-07-01 Novartis Ag Tryptase inhibitor
US6579698B1 (en) 1996-09-24 2003-06-17 The Procter & Gamble Company Stabilized proteinaceous protease inhibitors and variants thereof
US7001884B2 (en) * 2001-06-18 2006-02-21 Regents Of The University Of Michigan Eglin c based drugs for treatment of disease

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2125047B (en) * 1982-08-09 1986-02-19 Ciba Geigy Ag Yeast hybrid vectors and their use for the production of polypeptides
DE3324534A1 (de) * 1983-07-07 1985-01-17 Ciba-Geigy Ag, Basel Modifizierte protease-inhibitoren, verfahren zu ihrer herstellung und daraus bereitete pharmazeutische mittel
GR80965B (en) * 1983-11-21 1985-03-20 Ciba Geigy Ag Method for the preparation of protease inhibitors
US4711848A (en) * 1984-03-14 1987-12-08 Zymogenetics, Inc. Site specific mutagenesis in alpha-1-antitrypsin
DE3585969D1 (de) * 1984-06-14 1992-06-11 Chiron Corp Protease-inhibitoren des alpha-1-antitrypsin typs mit modifizierter aktiever stelle und deren herstellung.
HU204563B (en) * 1984-12-06 1992-01-28 Synergen Biolog Inc Process for producing recombinant serine-protease inhibitors and dns sequencyes for them
GB2188322A (en) * 1986-03-26 1987-09-30 Bayer Ag Aprotinin and analogues thereof produced by a recombinant host
GB2199582A (en) * 1987-01-07 1988-07-13 Bayer Ag Analogues of pancreatic secretory trypsin inhibitor

Also Published As

Publication number Publication date
EP0332576A3 (en) 1990-09-12
JP2716191B2 (ja) 1998-02-18
US5079229A (en) 1992-01-07
DD283645A5 (de) 1990-10-17
IE62993B1 (en) 1995-03-08
HU209401B (en) 1994-05-30
EP0332576B1 (de) 1994-04-06
FI96116B (fi) 1996-01-31
KR890014735A (ko) 1989-10-25
CA1339105C (en) 1997-07-29
DK107389D0 (da) 1989-03-06
AU623881B2 (en) 1992-05-28
NO178870C (no) 1996-06-19
PT89916A (pt) 1989-11-10
DE58907373D1 (de) 1994-05-11
ES2063161T3 (es) 1995-01-01
ATE103930T1 (de) 1994-04-15
KR0134377B1 (ko) 1998-04-20
EP0332576A2 (de) 1989-09-13
FI891020A0 (fi) 1989-03-03
DK107389A (da) 1989-09-08
AU3095989A (en) 1989-09-07
NO890932D0 (no) 1989-03-06
IL89496A0 (en) 1989-09-10
NO890932L (no) 1989-09-08
NO178870B (no) 1996-03-11
FI96116C (fi) 1996-05-10
JPH029392A (ja) 1990-01-12
TW211522B (fi) 1993-08-21
IE890719L (en) 1989-09-07
HUT50503A (en) 1990-02-28
PT89916B (pt) 1994-05-31
ZA891679B (en) 1989-10-25
NZ228208A (en) 1990-08-28

Similar Documents

Publication Publication Date Title
FI882007A0 (fi) Menetelmä steroidi-5- -reduktaasin inhibiittorien valmistamiseksi
FI893158L (fi) Menetelmä tetrahydrofolaattien valmistamiseksi
FI891711L (fi) Menetelmä diorganodialkoksisilaanien valmistamiseksi
BR8907457A (pt) Inibidores de interleucina-1
FI883052L (fi) Menetelmä puun suojaamiseksi
FI890123A0 (fi) Menetelmä valmistaa terapeuttisesti vaikuttavia indolyylipiperidiiniyhdisteitä
KR890016060A (ko) N2--l-리신 유도체 및 이를 사용한 리시노프릴의 제조방법
KR900009566A (ko) 말레이미드류의 제조법
DK639589D0 (da) Forbraendingsproces
DK444889A (da) Hoejtryks-natriumdampudladningslampe
DK46388D0 (da) Indretning til boretaarn
FI891020L (fi) Menetelmä proteaasi-inhibiittoriaktiivisuutta omaavien egliinimutanttien valmistamiseksi
MX164735B (es) Un metodo para la determinacion de bilirrubina en solucion
KR900702433A (ko) 레퍼런스점 복귀방식
IT9020623A0 (it) procedimento
KR890013292A (ko) 녹화기반 조성 공법
FI891866L (fi) Menetelmä terapeuttisesti käyttökelpoisten sulfonanilidien valmistamiseksi
BR8805933A (pt) Metodo para testar enzimas
FI891256L (fi) Aryylisulfonyylialkyyliamidien synteesimenetelmä
DK69489A (da) Aspartattranscarbamylase-inhibitorer
KR900002722U (ko) 연탄제조용 윤전기의 압축대
ATA204288A (de) Betteinsatz
NO903496L (no) Fremgangsmaate for metanomdanning.
DE3877180D1 (de) Dickenmessverfahren.
IT8967056A0 (it) Procedimento di immunizzazione ma gnetica in particolare per mezzi navali

Legal Events

Date Code Title Description
BB Publication of examined application
PC Transfer of assignment of patent

Owner name: NOVARTIS AG

MM Patent lapsed

Owner name: NOVARTIS AG

Owner name: UCP GEN-PHARMA AG